Halozyme Therapeutics (HALO) Appoints Interim CFO Amid Growth Plans

Halozyme Therapeutics, Inc. (NASDAQ:HALO) is one of the most undervalued growth stocks to buy, according to analysts. On March 12, Halozyme Therapeutics, Inc. (NASDAQ:HALO) announced the appointment of David Ramsay as the interim Chief Financial Officer, pending the appointment of a permanent CFO. Halozyme Therapeutics, Inc. (HALO) Appoints Interim CFO Amid Growth Plans Likoper/Shutterstock.com Ramsay takes over as CFO with over 30 years of experience in strategic financial leadership across the biotech ...